RxDoctor Payments Data

Maria Basedow, DO

Family Medicine · State College, PANPI 1689108060

Payments from drug & device makers

$1,651in general payments, 2019–2025

Across 104 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$406
  • AbbVie$390
  • Lilly USA, LLC$261
  • Novo Nordisk$126
  • Exact Sciences$67
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$67
  • plus $333 from 10 others

What the payments were for

  • Food & beverage$1,651100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,651 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,655
Medicare patients
200
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$45,802
EliquisApixaban40$33,018
TrulicityDulaglutide19$32,523
OzempicSemaglutide21$27,205
XareltoRivaroxaban16$10,808
Breo ElliptaFluticasone/Vilanterol14$8,779
Repatha SureclickEvolocumab13$6,273
Levothyroxine Sodium218$2,717
SynthroidLevothyroxine Sodium34$2,070
Atorvastatin Calcium188$1,785
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,720
Metoprolol Succinate66$1,503
Omeprazole134$1,441
Potassium Chloride49$1,194
Amlodipine Besylate141$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$406$33,01840 claims
Lilly USA, LLCTrulicity, Olanzapine$261$32,95334 claims
Novo NordiskOzempic$126$27,20521 claims
GSKBreo Ellipta$61$8,77914 claims
AbbVieSynthroid$390$2,07034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →